MX2022016406A - Metodos para tratar el cancer o enfermedad de von-hippel lindau usando una combinacion de un inhibidor de hif-2 alpha y lenvatinib. - Google Patents
Metodos para tratar el cancer o enfermedad de von-hippel lindau usando una combinacion de un inhibidor de hif-2 alpha y lenvatinib.Info
- Publication number
- MX2022016406A MX2022016406A MX2022016406A MX2022016406A MX2022016406A MX 2022016406 A MX2022016406 A MX 2022016406A MX 2022016406 A MX2022016406 A MX 2022016406A MX 2022016406 A MX2022016406 A MX 2022016406A MX 2022016406 A MX2022016406 A MX 2022016406A
- Authority
- MX
- Mexico
- Prior art keywords
- von
- lenvatinib
- hif
- methods
- lindau disease
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063042307P | 2020-06-22 | 2020-06-22 | |
| US202163146915P | 2021-02-08 | 2021-02-08 | |
| PCT/US2021/038172 WO2021262563A1 (en) | 2020-06-22 | 2021-06-21 | Methods for treating cancer or von-hippel lindau disease using a combination of a hif-2 alpha inhibitor and lenvatinib |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022016406A true MX2022016406A (es) | 2023-01-30 |
Family
ID=79281740
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022016406A MX2022016406A (es) | 2020-06-22 | 2021-06-21 | Metodos para tratar el cancer o enfermedad de von-hippel lindau usando una combinacion de un inhibidor de hif-2 alpha y lenvatinib. |
| MX2025014865A MX2025014865A (es) | 2020-06-22 | 2022-12-16 | Metodos para tratar el cancer o enfermedad de von-hippel lindau usando una combinacion de un inhibidor de hif-2 alpha y lenvatinib |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2025014865A MX2025014865A (es) | 2020-06-22 | 2022-12-16 | Metodos para tratar el cancer o enfermedad de von-hippel lindau usando una combinacion de un inhibidor de hif-2 alpha y lenvatinib |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230210838A1 (https=) |
| EP (1) | EP4168008B1 (https=) |
| JP (1) | JP7750884B2 (https=) |
| KR (1) | KR20230026493A (https=) |
| CN (1) | CN115803629A (https=) |
| AU (1) | AU2021296151A1 (https=) |
| BR (1) | BR112022026094A2 (https=) |
| CA (1) | CA3183852A1 (https=) |
| MX (2) | MX2022016406A (https=) |
| WO (1) | WO2021262563A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115463217B (zh) * | 2021-06-11 | 2024-03-12 | 深圳埃格林医药有限公司 | 己酸羟孕酮在增强肿瘤治疗效果中的应用 |
| CN119731864A (zh) | 2023-02-28 | 2025-03-28 | 株式会社Lg新能源 | 电化学装置用分隔件和包括其的电化学装置 |
| AU2024248799A1 (en) * | 2023-03-31 | 2025-10-23 | Daiichi Sankyo Company, Limited | Combination of anti-CDH6 antibody-drug conjugate and HIF-2alpha inhibitor |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016168510A1 (en) * | 2015-04-17 | 2016-10-20 | Peloton Therapeutics, Inc. | Combination therapy of a hif-2-alpha inhibitor and an immunotherapeutic agent and uses thereof |
| WO2018031680A1 (en) * | 2016-08-10 | 2018-02-15 | Fronthera U.S. Pharmaceuticals Llc | Novel compounds, uses and methods for their preparation |
| WO2020081695A1 (en) * | 2018-10-17 | 2020-04-23 | Nikang Therapeutics, Inc. | Indane derivatives as hypoxia inducible factor-2(alpha) inhibitors |
-
2021
- 2021-06-21 JP JP2022578935A patent/JP7750884B2/ja active Active
- 2021-06-21 CN CN202180049537.5A patent/CN115803629A/zh active Pending
- 2021-06-21 KR KR1020237002565A patent/KR20230026493A/ko active Pending
- 2021-06-21 AU AU2021296151A patent/AU2021296151A1/en active Pending
- 2021-06-21 CA CA3183852A patent/CA3183852A1/en active Pending
- 2021-06-21 EP EP21828761.3A patent/EP4168008B1/en active Active
- 2021-06-21 BR BR112022026094A patent/BR112022026094A2/pt unknown
- 2021-06-21 MX MX2022016406A patent/MX2022016406A/es unknown
- 2021-06-21 US US18/009,115 patent/US20230210838A1/en active Pending
- 2021-06-21 WO PCT/US2021/038172 patent/WO2021262563A1/en not_active Ceased
-
2022
- 2022-12-16 MX MX2025014865A patent/MX2025014865A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4168008A1 (en) | 2023-04-26 |
| JP7750884B2 (ja) | 2025-10-07 |
| JP2023531675A (ja) | 2023-07-25 |
| MX2025014865A (es) | 2026-01-07 |
| US20230210838A1 (en) | 2023-07-06 |
| EP4168008B1 (en) | 2026-03-18 |
| CN115803629A (zh) | 2023-03-14 |
| CA3183852A1 (en) | 2021-12-30 |
| EP4168008A4 (en) | 2024-08-07 |
| WO2021262563A1 (en) | 2021-12-30 |
| AU2021296151A1 (en) | 2023-02-02 |
| BR112022026094A2 (pt) | 2023-01-17 |
| KR20230026493A (ko) | 2023-02-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2023002497A1 (es) | Uso de inhibidores de bet como tratamiento para la mielofibrosis | |
| CO2020015758A2 (es) | Compuestos de purinona y su uso en el tratamiento del cáncer | |
| AR072442A1 (es) | Metodo para la terapia del cancer, uso, kit | |
| MX2025014865A (es) | Metodos para tratar el cancer o enfermedad de von-hippel lindau usando una combinacion de un inhibidor de hif-2 alpha y lenvatinib | |
| AR119158A1 (es) | Tratamientos de angioedema hereditario | |
| MX2021014161A (es) | Metodos de tratamiento del sindrome de sjogren utilizando un inhibidor de la tirosina quinasa de bruton. | |
| CL2021003032A1 (es) | Métodos de tratamiento de la urticaria crónica espontánea utilizando un inhibidor de la tirosina quinasa de bruton | |
| MX2018012165A (es) | Metodos de tratamiento de canceres pediatricos. | |
| CL2023002549A1 (es) | Ciertos compuestos de pladienolida y métodos de uso (divisional). | |
| CO2022016153A2 (es) | Inhibidores de il4i1 y métodos de uso | |
| MX2022008216A (es) | Tratamiento de cancer en combinacion usando un antagonista de pd-1, un antagonista de ilt4 y lenvatinib o sales del mismo. | |
| MX2023004554A (es) | Uso de benzodiazepinas para aumentar la sensibilidad a la psilocibina despues de un regimen cronico de isrs. | |
| AR119159A1 (es) | Tratamientos de angioedema | |
| MX2022012351A (es) | Administracion conjunta de mirdametinib y lifirafenib para uso en el tratamiento de canceres. | |
| MX2025014866A (es) | Metodos para tratar el cancer o enfermedad de von-hippel lindau usando una combinacion de un antagonista del pd-1, inhibidor de hif-2 alpha y lenvatinib o una sal aceptable farmeuticamente de estos | |
| MX2021007330A (es) | Composiciones y métodos terapéuticos para tratar cáncer usando ácido 6, 8-bis-benciltio-octanoico y un inhibidor de autofagia. | |
| WO2021262562A3 (en) | Methods for treating cancer or von-hippel lindau disease using a combination of a pd-1 antagonist, a hif-2 alpha inhibitor, and lenvatinib or a pharmaceutically acceptable salt thereof | |
| CO2021011319A2 (es) | Tratamientos combinados para su uso en el tratamiento del cáncer | |
| BR112022012081A2 (pt) | Método para tratar câncer, kit, e, uso de uma combinação terapêutica | |
| AR131842A1 (es) | Métodos para tratar gliomas | |
| MX2024001892A (es) | Una combinacion terapeutica que comprende un antagonista de tigit, un antagonista de pd-1 y uno o varios agentes quimioterapeuticos. | |
| NZ760040A (en) | Methods of treating brain tumors using combination therapy | |
| MX2023014234A (es) | Nuevo uso terapeutico de los inhibidores de la yodotironina desyodasa de tipo 2 (d2). | |
| AR126393A1 (es) | Terapia combinada para el tratamiento de enfermedades hepáticas | |
| BR112022000734A2 (pt) | Método para tratar câncer em um paciente, uso de composto 1, e, composto 1 |